Save
1 Steps
Maximum: 1 CME cr.
Sign in to view your progression
Case Study Background
Learning Objectives
Target Audience
Accreditation Information
Disclosures

This educational programme features multiple patient cases focusing on the following themes:

  • Case 1 (Safety Case, First-line therapy: Hepatotoxicity)
  • Case 2 (Safety Case, Second-line immunotherapy: Endocrine toxicity)
  • Case 3 (Drug efficacy, Second-line Immunotherapy)
  • Case 4 (Safety Case, First-line therapy: Skin toxicity)

The program focuses on several treatment scenarios and reviews the latest results of clinical trials assessing checkpoint inhibitors in patients with bladder cancer, in order to help physicians offer a more tailored approach to treatment.

​Upon completion of this educational activity, the participant should be able to:

  • - Describe the current management of platinum-treated metastatic urothelial cancer (mUC)
  • - Describe the current management of platinum-ineligible mUC
  • - Identify key immune-related adverse events
  • - Discuss how patients are being managed using case studies as examples

This program is designed for urologists, medical oncologists, radiation oncologists, residents, and fellows who have an interest in immunotherapy and systemic treatments for bladder cancer around the world who are SIU members or SIU Academy-registered members.

This program is accredited by the European Accreditation Council for Continuing Medical Education (EACCME).

The credits for the users of the module will be 1 European CME credit (ECMEC®) for every hour (60 minutes of actual e-learning excluding introductions etc.) of use, provided that the users have completed a module and have passed the relevant assessment.

Faculty Disclosures and Credentials

CHAIR
Dr. Michiel van der Heijden
Medical Oncologist, Netherlands Cancer Institute
Disclosures: Advisory boards BMS, AstraZeneca, Roche, Merck, Seattle Genetics, Astellas, Janssen

SCIENTIFIC COMMITTEE MEMBERS
Dr. Srikala Sridhar
Medical Oncologist, Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Disclosures: Advisory Boards – Merck, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer, Janssen, Astellas


Prof. Dr. med. Axel S. Merseburger
Chairman of the Department of Urology, University of Lübeck
Disclosures: Advisory Boards/Speaker – Merck, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer, Janssen, Astellas, Ferring, Ipsen, Takeda

Applications of Immunotherapy in Bladder Cancer
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings